inocul
gnotobiot
pig
oralyintranas
human
noroviru
strain
viruslik
particl
vlp
immunostimul
complex
iscom
mutant
e
coli
lt
toxin
mlt
mucos
adjuv
assess
intestin
system
antibodi
cytokin
respons
homolog
protect
vaccin
induc
high
rate
seroconvers
coproconvers
vlpmlt
vaccin
induc
serum
cytokin
cytokin
secret
cell
wherea
vlpiscom
vaccin
induc
bias
respons
significantli
elev
igm
iga
igg
antibodysecret
cell
intestin
nevertheless
vaccin
induc
increas
protect
rate
viral
shed
diarrhea
compar
control
howev
control
shed
viru
human
norovirus
hunov
constitut
major
caus
nonbacteri
epidem
gastroenter
worldwid
caus
signific
diseas
burden
associ
numer
outbreak
set
nurs
home
hospit
cruis
ship
militari
asymptomat
infect
hunov
also
common
may
import
hunov
persontoperson
transmiss
current
nov
vaccin
avail
human
anim
recombin
nov
capsid
express
vlp
constitut
safe
altern
develop
hunov
vaccin
particl
antigen
similar
nativ
virion
produc
high
yield
use
baculoviru
system
stabl
low
ph
make
suitabl
oral
administr
mimick
natur
rout
hunov
infect
differ
strategi
use
produc
hunov
vlp
antigen
evalu
mice
human
gi
norwalkviru
nv
vlp
administ
intranas
balbc
mice
presenc
absenc
mucos
adjuv
mutant
escherichia
coli
heatlabil
toxin
mlt
low
dose
nv
vlp
antigen
higher
dose
induc
specif
serum
igg
fecal
vagin
antibodi
respons
use
mlt
enhanc
immun
respons
oral
administr
nv
vlp
human
volunt
elicit
seroconvers
increas
number
nvspecif
iga
antibodysecret
cell
asc
peripher
blood
mononuclear
cell
pbmc
volunt
develop
nvspecif
mucos
iga
antibodi
mlt
singl
amino
acid
substititut
posit
diminish
toxic
still
retain
adjuvant
administ
oral
immunostimul
complex
iscom
also
constitut
altern
antigen
deliveri
system
adjuv
cagelik
structur
compos
subunit
built
interact
surfact
saponin
lipid
particl
cholesterol
phospholipid
previou
studi
use
gnotobiot
gn
pig
model
show
oral
prime
attenu
human
rotaviru
hrv
follow
booster
dose
rv
inner
capsid
protein
vlp
combin
iscom
induc
protect
rate
diarrhea
viru
shed
similar
pig
receiv
threedos
attenu
human
rotaviru
atthrv
vaccin
boost
antibodi
titer
asc
respons
vaccin
regimen
provid
high
protect
rate
diarrhea
challeng
virul
wahrv
induc
high
viru
neutral
mucos
iga
antibodi
titer
hrv
intestin
content
gn
pig
similar
strategi
use
iscombas
hunov
vlp
vaccin
yet
test
immun
hunov
complex
larg
undefin
due
absenc
relev
nov
anim
model
enter
diseas
limit
associ
human
volunt
studi
abo
histoblood
group
type
secretor
statu
identifi
genet
factor
may
influenc
suscept
noroviru
nov
infect
andor
diseas
human
recent
demonstr
pig
andor
h
phenotyp
increas
diarrhea
viral
shed
rate
compar
gn
pig
nona
h
phenotyp
inocul
hunov
strain
howev
snow
mountain
viru
smv
infect
depend
histoblood
group
secretor
statu
recent
studi
show
vlp
bristollik
strain
implic
variou
outbreak
global
last
year
bind
saliva
secretorposit
individu
regardless
blood
type
rais
question
role
antigen
certain
hunov
strain
bind
enter
target
cell
local
immun
hunov
difficult
assess
studi
either
mice
human
done
gn
pig
constitut
valuabl
model
studi
system
local
immun
enter
pathogen
due
resembl
gut
physiolog
human
lack
matern
antibodi
pathogen
exposur
allow
assess
primari
immun
respons
recent
conduct
detail
studi
local
system
cytokin
antibodi
respons
hunov
strain
gn
pig
model
show
strain
induc
antibodi
cytokin
respons
local
system
studi
evalu
system
local
immun
respons
gn
pig
one
oral
follow
two
booster
dose
hunov
strain
vlp
mlt
iscom
adjuv
prior
viral
challeng
homolog
viru
induct
protect
strain
vlp
produc
use
recombin
baculoviru
system
previous
describ
minor
modif
briefli
recombin
baculoviru
contain
capsid
gene
sequenc
strain
construct
baculoviru
stock
produc
plaqu
purifi
vlp
produc
infect
spodoptera
frugiperda
cell
baculoviru
stock
multipl
infect
moi
incub
harvest
postinocul
day
pid
supernat
collect
centrifug
x
g
min
pellet
cell
assembl
vlp
purifi
cscl
densiti
gradient
ultracentrifug
previous
describ
particl
integr
reactiv
test
immuneelectron
microscopi
iem
antigen
enzym
link
immunosorb
assay
elisa
western
blot
protein
concentr
evalu
bradford
quantif
method
biorad
hercul
ca
steril
vlp
prepar
assess
bacteriolog
cultur
assay
use
blood
agar
plate
thioglycol
broth
room
temperatur
rt
two
week
endotoxin
level
measur
use
limulu
amebocyt
lysat
assay
associ
cape
cod
wood
hole
mass
vlp
mix
licl
min
rt
incub
overnight
increas
capac
bind
iscom
matrix
licltreat
vlp
posit
charg
li
ion
mix
iscom
matrix
mg
iscom
per
mg
vlp
dialyz
nacl
solut
hr
associ
vlp
iscom
matrix
confirm
iem
use
mlt
contain
mutat
arginin
glycin
amino
acid
posit
protein
kindli
provid
j
clement
tulan
univers
medic
center
new
orlean
la
dose
use
studi
previous
determin
gn
pig
experi
lab
use
hrv
vlp
vlp
mix
mlt
mlt
per
mg
vlp
previous
dilut
phosphat
buffer
salin
pb
ph
immedi
preced
use
singl
aliquot
pool
origin
human
fecal
sampl
identifi
strain
genbank
access
number
use
oral
inocul
gn
pig
use
dose
approxim
genom
equival
ge
ml
uniform
inoculum
pool
prepar
dilut
hunov
origin
inoculum
minim
essenti
medium
mem
gibco
invitrogen
carlsbad
ca
process
vortex
centrifug
g
min
filtrat
follow
filter
subset
pig
challeng
one
oral
dose
ml
dilut
pool
inoculum
administ
ml
sodium
bicarbon
neutral
stomach
acid
nearterm
pig
deriv
surgeri
maintain
steril
isol
unit
previous
describ
gn
pig
use
studi
alloc
one
three
group
ah
phenotyp
pig
day
age
determin
hemagglutin
inhibit
hi
use
buccal
cell
collect
test
previous
describ
daili
rectal
swab
collect
diarrhea
score
note
record
pid
describ
previous
sampl
score
consid
diarrheic
diarrhea
cumul
score
pig
repres
sum
daili
rectal
swab
score
pcd
mean
cumul
score
group
sum
pig
diarrhea
cumul
score
divid
number
pig
group
viral
shed
determin
use
rectal
swab
fluid
dilut
intestin
content
ic
rtpcr
use
primer
pair
mon
target
rdrp
region
hunov
gii
use
condit
previous
describ
howev
unlik
previous
describ
sampl
inhibit
rtpcr
reveal
use
intern
control
retest
reextract
use
rneasi
mini
kit
qiagen
inc
valencia
ca
neg
control
rectal
swab
mock
inocul
pig
rnasefre
water
rna
extract
rtpcr
includ
assay
micropl
hybrid
assay
perform
confirm
product
specif
use
probe
specif
antigen
elisa
perform
previous
describ
cheetham
et
al
sampl
consid
posit
mean
absorb
nm
posit
coat
well
minu
mean
absorb
neg
coat
well
higher
mean
absorb
neg
control
well
plu
time
standard
deviat
immunocytochemistri
assay
perform
detect
antibodi
serum
ic
gn
pig
previous
describ
assay
recombin
baculoviru
express
capsid
use
infect
spodoptera
frugiperda
cell
hunov
antigen
sourc
recombin
baculoviru
infect
cell
mock
cell
infect
recombin
baculoviru
express
protein
ku
rotaviru
strain
subsequ
fix
use
formalin
pb
antibodi
titer
defin
reciproc
highest
serum
dilut
brownstain
cell
repres
nov
antibodi
complex
capsid
antigen
could
detect
segment
small
intestin
jejunum
ileum
spleen
blood
asept
collect
euthanasia
process
isol
mnc
popul
previous
describ
singl
mnc
suspens
tissu
blood
prepar
concentr
mnc
mncml
complet
medium
prepar
roswel
park
memori
institut
rpmi
gibco
enrich
fetal
bovin
serum
hydroxyethylpiperazin
ethanesulfon
acid
hepe
lglutamin
sodium
pyruv
nonessenti
amino
acid
gentamicinml
ampicilinml
elispot
detect
isotypespecif
igm
iga
igg
asc
conduct
use
previous
publish
method
briefli
plate
infect
capsid
gene
recombin
baculoviru
mock
plate
prepar
fix
describ
antibodi
detect
section
wash
deioniz
water
prior
use
singl
mnc
suspens
tissu
ad
duplic
well
well
plate
incub
hr
co
wash
three
time
pb
buffer
incub
hr
hrplabel
antibodi
goat
antipig
igm
kpl
iga
serotec
igg
kpl
plate
wash
three
time
pb
buffer
develop
tetramethylbenzidin
tmb
kpl
inc
hr
rt
number
virusspecif
asc
determin
count
blue
spot
well
use
light
microscop
report
number
virusspecif
asc
per
mnc
background
spot
evid
mock
plate
subtract
cytokin
elispot
detect
proinflammatori
csc
perform
previous
describ
minor
modif
ad
multiscreenip
steril
plate
millipor
bedford
concentr
well
cell
stimul
csclpurifi
viruslik
particl
vlp
phytohemagglutinin
posit
control
rpmi
neg
control
plate
incub
co
h
number
csc
count
use
immunospot
seri
analyz
cellular
technolog
ltd
cleveland
oh
express
csc
per
mnc
csc
number
comput
number
csc
control
rpmistimul
cell
subtract
vlpstimul
cell
blood
collect
pig
pid
intestin
content
collect
euthanasia
pid
pid
serum
sampl
process
store
c
ic
sampl
dilut
mem
proteas
inhibitor
cocktail
prevent
cytokin
degrad
serum
ic
immedi
frozen
test
elisa
test
perform
detect
previous
describ
addit
cytokin
elisa
detect
porcin
cytokin
also
perform
antihu
kit
biosourc
camarillo
ca
plate
coat
polyclon
antihuman
sampl
ad
biotinlabel
monoclon
antibodi
mab
human
biosourc
ad
follow
addit
streptavidinhrp
biosourc
tmb
kpl
standard
curv
gener
use
recombin
porcin
biosourc
camarillo
ca
r
system
biosourc
computergener
fourparamet
curvefit
use
calcul
concentr
cytokin
detect
sensit
limit
reaction
pgml
cytokin
concentr
asc
pid
csc
pid
number
compar
among
within
group
use
kruskalw
rank
sum
test
nonparametr
oneway
analysi
varianc
anova
follow
duncan
multipl
rang
test
use
compar
antibodi
gmt
among
differ
group
seroconvers
coproconvers
rate
percentag
pig
diarrhea
shed
compar
use
fisher
exact
test
statist
signific
assess
p
pig
type
presenc
andor
h
antigen
buccal
cell
hemagglutin
inhibit
hi
pig
use
studi
h
phenotyp
h
phenotyp
one
pig
non
ah
type
belong
vaccin
group
pig
euthan
pid
pig
includ
control
challeng
euthan
h
phenotyp
subset
pig
group
euthan
pid
pid
receiv
challeng
oral
diarrhea
viral
shed
evalu
tabl
vlpiscom
vaccin
group
pig
diarrhea
day
vlpmlt
group
none
pig
develop
diarrhea
challeng
howev
pig
control
group
iscom
mlt
diarrhea
challeng
none
pig
either
vaccin
group
detect
viru
shed
rtpcr
microwel
hybrid
antigenelisa
howev
control
group
pig
shed
viru
mean
day
diarrhea
mean
diarrhea
score
vlpiscom
vlpmlt
vaccin
group
significantli
reduc
compar
control
group
gn
pig
vlpiscom
vaccin
group
protect
rate
diarrhea
vlpmlt
group
group
protect
rate
viral
shed
detail
antibodi
respons
serum
ic
depict
fig
seroconvers
coproconvers
rate
shown
tabl
onehundredperc
pig
receiv
either
vaccin
regimen
vlpiscom
vlpmlt
seroconvert
viru
challeng
pid
tabl
compar
none
prechalleng
control
igm
antibodi
first
detect
pid
low
titer
oral
prime
dose
vlpiscom
vlpmlt
vaccin
respect
increas
significantli
pid
vaccin
group
compar
control
fig
howev
pid
igm
antibodi
titer
vlpmlt
group
significantli
higher
control
iga
antibodi
first
detect
serum
pid
vlpiscom
vlpmlt
group
respect
significantli
elev
pid
pid
vaccin
group
compar
control
serum
igg
antibodi
first
detect
low
level
pid
vaccin
group
significantli
higher
control
prechalleng
pid
significantli
higher
titer
igg
antibodi
detect
vlpiscom
group
rang
compar
vlpmlt
group
gmt
rang
howev
postchalleng
pid
igg
gmt
remain
vlpiscom
group
although
one
pig
titer
increas
vlpmlt
group
igg
antibodi
gmt
increas
pid
gmt
compar
pid
postchalleng
antibodi
titer
significantli
higher
group
compar
control
fig
igm
iga
igg
antibodi
titer
also
measur
ic
euthan
pig
challeng
pid
postchalleng
pid
onehundredperc
pig
receiv
vlpiscom
receiv
vlp
mlt
vaccin
regimen
coproconvert
pid
tabl
either
iga
igg
antibodi
ic
prechalleng
antibodi
igm
iga
igg
titer
significantli
elev
ic
vlpiscom
vaccin
group
compar
group
fig
titer
increas
postchalleng
vlpiscom
except
pig
diarrhea
pcd
iga
igg
respect
titer
increas
iga
igg
respect
vlpmlt
group
pid
compar
pid
iga
igg
antibodi
significantli
increas
postchalleng
compar
control
control
pig
coproconvert
viral
challeng
iga
titer
ic
tabl
result
elispot
assay
detect
virusspecif
asc
control
gn
pig
euthan
pid
pid
shown
fig
number
igm
iga
igg
asc
elicit
vlpiscom
vlp
mlt
group
significantli
higher
control
pid
pid
tissu
except
igm
postand
iga
igg
prechalleng
blood
pid
higher
number
iga
igg
asc
elicit
vaccin
regimen
local
intestin
compar
system
spleen
highest
number
iga
igg
asc
detect
intestin
vlpiscom
group
pid
pid
respect
asc
mnc
respect
pid
significantli
higher
number
igm
asc
detect
intestin
vlpiscom
vaccin
pig
compar
group
pid
higher
number
detect
challeng
asc
mnc
vlpmlt
vaccin
group
fewer
igm
asc
respect
detect
pid
spleen
preand
postchalleng
igm
asc
number
also
significantli
higher
vaccin
group
compar
control
although
lower
number
compar
observ
intestin
iga
igg
asc
number
also
significantli
higher
intestin
vlp
iscom
pig
compar
group
preand
postchalleng
although
boost
magnitud
respons
either
vaccin
observ
postchalleng
consist
protect
observ
spleen
iga
igg
asc
number
significantli
higher
vaccin
group
compar
control
preand
postchalleng
asc
isotyp
significantli
elev
spleen
postchalleng
vlpmlt
versu
vlpiscom
group
significantli
higher
number
iga
igg
asc
observ
blood
pbmc
vlpmlt
vaccin
pig
prechalleng
compar
vlpiscom
control
vaccin
group
postchalleng
compar
control
cytokin
elisa
result
summar
pid
nonsignific
transient
increas
proinflammatori
cytokin
detect
control
group
pid
increas
level
observ
serum
vaccin
group
cytokin
detect
constitut
serum
pig
group
birth
significantli
elev
serum
vlpmlt
group
pid
compar
group
transient
significantli
elev
peak
cytokin
detect
serum
vlpmlt
group
pid
one
oral
dose
vaccin
signific
increas
postchalleng
pid
iscomvlp
vaccin
pig
low
peak
detect
pid
increas
significantli
challeng
pid
pid
compar
control
cytokin
significantli
elev
serum
vaccin
group
pid
compar
control
serum
vlpmlt
pig
pid
compar
group
cytokin
significantli
elev
serum
vlpmlt
vaccin
pig
pid
pgml
serum
vaccin
group
postchalleng
although
significantli
compar
control
cytokin
peak
pgml
pid
serum
vlpiscom
pig
later
pgml
pid
vlpmlt
group
higher
significantli
level
also
detect
serum
control
group
viral
challeng
pid
cytokin
concentr
measur
ic
pig
euthanasia
pid
pid
data
shown
low
moder
cytokin
concentr
detect
ic
vaccin
group
pidpcd
significantli
higher
ic
control
presum
due
instabl
secret
cytokin
ic
significantli
higher
concentr
pgml
cytokin
detect
ic
vlpmlt
group
one
week
postchalleng
pid
compar
group
gener
higher
number
csc
elicit
vaccin
group
compar
control
postchalleng
fig
howev
system
tissu
spleen
pbmc
vlpmlt
pig
csc
number
significantli
elev
csc
mnc
csc
mnc
respect
prechalleng
csc
number
also
significantli
elev
spleen
csc
number
pbmc
vlpmlt
pig
prechalleng
postchalleng
highest
number
proinflammatori
csc
detect
blood
pbmc
vaccin
group
although
significantli
higher
compar
control
spleen
significantli
higher
number
csc
observ
vlpiscom
csc
mnc
respect
vlp
mlt
csc
mnc
respect
vaccin
pig
compar
control
significantli
higher
number
csc
detect
vlpiscom
pig
tissu
blood
csc
mnc
compar
group
csc
significantli
elev
intestin
significantli
higher
number
csc
observ
blood
pbmc
vaccin
group
csc
mnc
mltvlp
mnc
iscomvlp
compar
control
hunov
infect
usual
selflimit
transient
howev
increas
number
nov
outbreak
worldwid
particularli
one
associ
strain
impact
set
nurs
home
hospit
militari
indic
develop
effect
vaccin
would
beneficiari
studi
evalu
immunogen
vlp
administ
three
dose
one
oral
conjunct
two
adjuv
iscom
mlt
evalu
protect
elicit
vaccin
regimen
oral
challeng
none
vaccin
pig
either
vlpiscom
vlpmlt
group
shed
viru
protect
rate
diarrhea
respect
howev
postchalleng
control
pig
shed
detect
viru
coproconvert
iga
antibodi
pcd
previou
studi
lab
show
pig
andor
h
phenotyp
increas
diarrhea
viral
shed
rate
compar
nona
h
gn
pig
infect
strain
pig
studi
type
ah
phenotyp
pig
challeng
hunov
h
phenotyp
conclud
ah
phenotyp
influenc
outcom
studi
howev
older
age
gn
pig
challeng
could
play
role
lack
viru
shed
detect
control
group
previou
studi
inocul
pig
earlier
age
compar
mayb
gn
pig
resist
infect
older
age
howev
pig
iscom
mlt
control
group
diarrhea
compar
pig
vlpiscom
group
assum
viral
replic
undetect
low
level
may
occur
control
pig
immunogen
hunov
vlp
administ
alon
mlt
evalu
mice
vlp
induc
system
mucos
fecal
vagin
immun
respons
immun
respons
nv
vlp
also
determin
human
volunt
howev
previou
exposur
hunov
confound
variabl
interpret
magnitud
immun
respons
elicit
vlp
therefor
gn
anim
pig
calv
constitut
valuabl
model
studi
local
system
immun
respons
anim
nov
vlp
hunov
vlp
high
seroconvers
rate
observ
studi
vaccin
group
prechalleng
similar
previous
observ
human
mice
oral
immun
dose
nv
vlp
serum
antibodi
respons
also
induc
gn
calv
immun
bovin
noroviru
bonov
vlp
variou
adjuv
includ
mlt
iscom
rout
inocul
low
moder
serum
igg
antibodi
titer
gmt
detect
prechalleng
calv
immun
bonov
vlpmlt
postchalleng
highest
increas
serum
igg
antibodi
titer
also
detect
group
follow
vlpmltoral
vaccin
calv
ic
detect
significantli
elev
iga
igg
antibodi
vaccin
group
postchalleng
pid
vlpiscom
group
igm
iga
highest
igg
antibodi
titer
significantli
elev
prechalleng
compar
group
like
local
presenc
antibodi
also
reflect
significantli
elev
number
asc
also
iga
highest
gut
challeng
play
role
protect
induc
vlpiscom
vaccin
mucos
saliva
fece
vagin
semen
wash
antinv
iga
also
observ
volunt
oral
immun
dose
nv
vlp
without
adjuv
use
studi
moreov
studi
coproconvers
rate
iga
igg
antibodi
ic
prechalleng
higher
vlpmlt
group
vlpiscom
group
nonadjuv
nv
vlp
human
like
reflect
enhanc
intestin
antibodi
respons
induc
mucos
adjuv
high
iga
antibodi
titer
observ
ic
vlp
iscom
group
differ
result
bonov
vlp
studi
fecal
iga
antibodi
detect
calv
receiv
either
dose
vlpmltin
also
contrast
pig
studi
fecal
igg
antibodi
detect
prechalleng
calv
vlpiscom
vlpmlt
oral
group
howev
bonov
challeng
fecal
igg
antibodi
elicit
calv
vaccin
regimen
compar
intestin
system
asc
respons
highest
number
asc
three
isotyp
detect
local
intestin
vlpiscom
vaccin
pig
find
reinforc
administr
vlp
oral
plu
combin
rout
constitut
effici
vaccin
strategi
like
mimick
natur
rout
hunov
infect
also
reflect
particul
immunogen
natur
vlp
efficaci
iscom
adjuv
induc
mucos
antibodi
especi
iga
magnitud
asc
respons
intestin
howev
boost
challeng
like
reflect
high
degre
protect
observ
viru
shed
higher
prechalleng
asc
number
elicit
intestin
vaccin
pig
studi
compar
detect
pid
gn
pig
oral
inocul
challeng
inoculum
multipl
dose
hunov
nonrepl
vlp
vaccin
may
need
elicit
strong
immun
respons
possibl
protect
low
moder
significantli
elev
igm
iga
igg
asc
respons
detect
postchalleng
system
spleen
blood
vaccin
group
compar
control
induc
higher
magnitud
vlpmlt
group
compar
vlpiscom
group
except
igm
igg
pbmc
system
iga
asc
respons
also
detect
pbmc
volunt
oral
vaccin
nv
vlp
number
asc
elicit
differ
significantli
among
differ
vlp
dose
howev
unlik
pig
model
intestin
asc
respons
could
evalu
human
volunt
rel
higher
concentr
pgml
compar
cytokin
ic
vlpmlt
pig
corrobor
concentr
found
serum
like
repres
boost
memori
respons
previous
elicit
hunov
vlp
increas
concentr
also
detect
ic
vlpmlt
vaccin
pig
postchalleng
human
volunt
studi
level
measur
pbmc
cultur
supernat
nvvlp
vaccine
vitro
nvvlp
stimul
signific
increas
product
detect
pbmc
collect
day
first
oral
nv
vlp
immun
comparison
preimmun
level
howev
respons
detect
pbmc
supernat
volunt
receiv
high
dose
vlp
author
suggest
lack
respons
could
due
toler
induc
high
vlp
dose
concentr
significantli
higher
serum
vaccin
group
pid
serum
vlpmlt
group
pid
compar
group
adult
volunt
studi
detect
pbmc
cultur
supernat
concentr
also
evalu
detect
author
conclud
domin
respons
induc
nv
vlp
howev
must
interpret
care
cytokin
exist
evalu
therefor
complet
panel
cytokin
evalu
conclus
reach
also
evalu
concentr
anoth
cytokin
serum
gn
pig
significantli
higher
level
detect
pid
pid
vlpmlt
group
compar
group
play
import
role
modul
immun
respons
especi
intracellular
parasit
interestingli
increas
level
postchalleng
pid
pcd
serum
vaccin
group
parallel
proinflammatori
cytokin
perhap
reflect
effect
induc
antiinflammatori
proinflammatori
csc
respons
also
evalu
local
intestin
system
spleen
blood
knowledg
intestin
csc
respons
examin
previous
nov
infect
speci
vlpmlt
group
higher
proinflammatori
csc
number
system
tissu
prechalleng
compar
vlpiscom
group
balanc
csc
profil
prechalleng
coincid
complet
protect
viru
shed
diarrhea
observ
group
csc
number
significantli
elev
postchalleng
vlp
iscom
group
local
intestin
system
spleen
blood
compar
group
comparison
secret
csc
isol
blood
human
volunt
previous
immun
one
two
dose
nv
vlp
detect
csc
respons
enhanc
vlpiscom
group
suggest
iscom
may
influenc
respons
compar
lack
adjuv
nv
vlp
human
trial
conclus
vlpiscom
vlpmlt
vaccin
regimen
induc
high
rate
seroconvers
coproconvers
protect
viral
shed
diarrhea
compar
control
although
control
pig
shed
viru
diarrhea
significantli
higher
diarrhea
score
compar
vaccin
pig
prechalleng
vlp
iscom
vaccin
induc
higher
iga
igg
asc
system
local
iga
igg
antibodi
ic
significantli
elev
intestin
csc
postchalleng
contrast
vlpmlt
induc
higher
system
csc
number
prechalleng
highest
cytokin
respons
ic
postchalleng
collect
result
indic
vlpmlt
induc
balanc
respons
serum
prechalleng
wherea
vlpiscom
induc
bias
respons
prechalleng
significantli
higher
system
local
system
csc
respons
postchalleng
vaccin
induc
protect
upon
challeng
hunov
although
protect
diarrhea
less
effici
latter
group
base
data
use
adjuv
vlp
induc
balanc
immun
respons
significantli
elev
intestin
asc
mlt
bias
respons
significantli
higher
intestin
iga
igg
asc
iscom
induc
adequ
protect
knowledg
first
studi
evalu
immunogen
protect
potenti
gii
hunov
vlp
also
assess
detail
local
system
immun
respons
hunov
vlp
vaccin
prior
subsequ
homolog
viral
challeng
experiment
anim
model
fecal
viru
shed
diarrhea
seroconvers
protect
rate
coproconvers
gn
pig
vaccin
either
vlpiscom
vlpmlt
control
iscom
mlt
